Disclosed is the use of a pharmaceutical preparation comprising a) a physiological solution comprising peripheral blood mononuclear cells (PBMCs) or a subset thereof, or b) a supernatant of the solution a), wherein the solution a) comprises PBMCs or a subset thereof in a physiological solution free of PBMC-proliferating and PBMC-activating substances in the manufacture of a medicament for treating an internal inflammatory condition. Further disclosed is a method for preparing a pharmaceutical preparation comprising the steps of a) providing peripheral blood mononuclear cells (PBMCs) or a subset thereof, b) culturing the cells of step a) in a physiological solution free of PBMC-proliferating and PBMC-activating substances for at least 1 h, c) isolating the cells of step b) and/or the supernatant thereof, and d) preparing the pharmaceutical preparation using the cells and/or the supernatant of step c) .
